Finch Therapeutics Group

Company snapshot

Finch Therapeutics has a portfolio of microbiome assets including CP101, a late-stage, investigational, orally administered microbiome candidate with positive clinical data from a Phase 2 randomized, placebo-controlled trial and a Phase 2 open-label trial in recurrent C. difficile infection (CDI). Additionally, Finch has pre-clinical assets that are designed to target ulcerative colitis, Crohn’s d

• 5 active pipeline program(s) linked via ClinicalTrials.gov.
• 33 US patent(s) indexed to this assignee profile.
• 5 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Finch Therapeutics Group. Not investment advice.

• Peer + 0 momentum

  Acurx Pharmaceuticals

  TA overlap score 20.4

Recent activity

Latest pipeline, patent, and corporate events for Finch Therapeutics Group.

1. Jun 5, 2026 Clinical update

   Full Spectrum Microbiota — Phase 2

2. Jun 5, 2026 Clinical update

   Fecal Microbiota Transplantation — Phase 1

3. Jun 5, 2026 Clinical update

   CP101 — Phase 2

4. May 23, 2026 Clinical update

   CP101 — Phase 3

5. May 23, 2026 Clinical update

   CP101 — Phase 2

View all clinical trial activity →

• What is Finch Therapeutics Group?

  Finch Therapeutics is a biotech organization headquartered in Somerville, USA. It trades on NYSE under ticker FNCHQ. Primary therapeutic focus areas include Clostridium Difficile Infection, Autism Spectrum Disorder, Recurrent C. Difficile Infection, Enterobacteriaceae Infections,

• Is Finch Therapeutics Group publicly traded?

  Yes. Finch Therapeutics Group is listed with ticker FNCHQ on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Finch Therapeutics Group develop or market?

  We link 2 drug profile(s) where Finch Therapeutics Group is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/finch-therapeutics-group#company-drugs.

• What are the latest developments for Finch Therapeutics Group?

  In the last 12 months our linked public records show 5 trial program update(s) and 2 US patent grant(s) tied to this profile.

• What therapeutic areas does Finch Therapeutics Group focus on?

  Finch Therapeutics Group focuses on Clostridium Difficile Infection, Autism Spectrum Disorder, Recurrent C. Difficile Infection based on our analysis of their pipeline programs and drug development activities.